IMO you are right on with your comment that TIS doesn't have the resources to pursue all of Vitrogro's potential applications simultaneously.
The decision (I think by Steven Mercer) to initially focus TIS's commercialisation on a single major application is a significant part of what makes so TIS special.
The road to riches of small biotech's with great ideas is littered with the carcasses of those companies that tried to do too much too soon.
A biotech that doesn't have its head in the clouds and doesn't try to ramp its own share price (with the intent of optimising future rights issues) is one that rewards investors and frustrates hot money.
cheers
Snapping
TIS Price at posting:
60.7¢ Sentiment: Buy Disclosure: Held
